Supernus Pharms Company Profile

What is the competitive landscape for SUPERNUS PHARMS

SUPERNUS PHARMS has five approved drugs.

There are forty-eight US patents protecting SUPERNUS PHARMS drugs. There is one tentative approval on SUPERNUS PHARMS drugs.

Summary for Supernus Pharms

US Patents:	48
Tradenames:	5
Ingredients:	4
NDAs:	5

Drugs and US Patents for Supernus Pharms

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Supernus Pharms	OXTELLAR XR	oxcarbazepine	TABLET, EXTENDED RELEASE;ORAL	202810-002	Oct 19, 2012	AB	RX	Yes	No	10,220,042
Supernus Pharms	QELBREE	viloxazine hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	211964-001	Apr 2, 2021		RX	Yes	No	11,458,143
Supernus Pharms	OXTELLAR XR	oxcarbazepine	TABLET, EXTENDED RELEASE;ORAL	202810-001	Oct 19, 2012	AB	RX	Yes	No	10,220,042
Supernus Pharms	OXTELLAR XR	oxcarbazepine	TABLET, EXTENDED RELEASE;ORAL	202810-001	Oct 19, 2012	AB	RX	Yes	No	9,119,791
Supernus Pharms	TROKENDI XR	topiramate	CAPSULE, EXTENDED RELEASE;ORAL	201635-001	Aug 16, 2013	AB1	RX	Yes	No	8,992,989		Y
Supernus Pharms	TROKENDI XR	topiramate	CAPSULE, EXTENDED RELEASE;ORAL	201635-003	Aug 16, 2013	AB1	RX	Yes	No	9,555,004		Y

Expired US Patents for Supernus Pharms

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Supernus Pharms	OSMOLEX ER	amantadine hydrochloride	TABLET, EXTENDED RELEASE;ORAL	209410-002	Feb 16, 2018	8,895,614
Supernus Pharms	OSMOLEX ER	amantadine hydrochloride	TABLET, EXTENDED RELEASE;ORAL	209410-004	Apr 22, 2020	8,895,615
Supernus Pharms	GOCOVRI	amantadine hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	208944-002	Aug 24, 2017	8,796,337
Supernus Pharms	OSMOLEX ER	amantadine hydrochloride	TABLET, EXTENDED RELEASE;ORAL	209410-001	Feb 16, 2018	8,987,333
Supernus Pharms	OSMOLEX ER	amantadine hydrochloride	TABLET, EXTENDED RELEASE;ORAL	209410-003	Feb 16, 2018	8,796,337
Supernus Pharms	OSMOLEX ER	amantadine hydrochloride	TABLET, EXTENDED RELEASE;ORAL	209410-002	Feb 16, 2018	RE39069

Paragraph IV (Patent) Challenges for SUPERNUS PHARMS drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	Extended-release Capsules	200 mg		2014-04-03
	Extended-release Tablets	150 mg and 300 mg		2013-04-12
	Extended-release Capsules	25 mg, 50 mg, and 100 mg		2014-05-12

International Patents for Supernus Pharms Drugs

Country	Patent Number	Estimated Expiration
Australia	2007319141
Japan	6316376
European Patent Office	4233915
Spain	2555066
Canada	2588296
World Intellectual Property Organization (WIPO)	2008061226

Supplementary Protection Certificates for Supernus Pharms Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2317997	2190050-1	Sweden		PRODUCT NAME: PHENTERMINE AND TOPIRAMATE; NAT. REG. NO/DATE: 59574-59577 20210617; FIRST REG.: IS IS/1/21/018/01-04 20210212
0138441	SPC/GB95/028	United Kingdom		PRODUCT NAME: TOPIRAMATE; REGISTERED: UK 0242/0301 19950718

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Supergen
• Supernus Pharms
• Superpharm